On April 16, 2020, an article by STAT national biotech columnist Adam Feuerstein leaked early, incomplete results Gilead Sciences clinical trial of remdesivir for COVID-19 without permission from the company.[9] The title of this exclusive story was "Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment."[10] Gilead shares jumped higher in after-hours trading immediately after the report published.[11] In a statement to CNBC, a University of Chicago spokesperson said, “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation."[11] Texas Democrat Rep. Lloyd Doggett, chair of the House Ways and Means Health Subcommittee, called for an investigation of how STAT obtained the leaked video. Rep. Doggett, an attorney, noted that "providing information that's designed to impact the stock market is not something that is permitted under federal securities law."[9]